Loading data for OPK — first visit, this takes a few seconds.

알림

OPKO Health Inc. (OPK)

NasdaqGS: OPK · 실시간 가격 · USD

1.48

+0.02 (1.37%)

종가 기준: Aug 21, 2026, 8:00 PM

1.48

-0.05%

애프터마켓: 5:59 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

1.37% (1D)

데이터 없음

매수호가	1.27
시가총액	1.1B
매출 (ttm)	587.9M
순이익 (ttm)	-72.89M
	1.49
	-0.07
	n/a
	-5.38
P/B (ttm)	0.93
P/S (ttm)	1.88
실적 발표일	Oct 28, 2026

매도호가	1.49
거래량	2,623,834
평균 거래량 (20일)	3,568,519
시가	1.49
전일 종가	1.46
일중 범위	1.46 - 1.52
52주 범위	0.98 - 1.73
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

OPK 소개

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical tria...

[더 보기]

산업 Diagnostics & Research

섹터 Healthcare

IPO 일자 Nov 2, 1995

직원 수 2,275

상장 거래소 NasdaqGS

티커 OPK

웹사이트 https://www.opko.com

전체 기업 정보

재무 실적

2025년 OPKO Health의 매출은 606.88M로, 전년 713.14M 대비 -14.9% 감소했습니다. 순이익은 -225.68M로, 324.02% 증가했습니다.

재무제표

어닝 서프라이즈

OPKO Health가 Jul 27, 2026에 분기 실적을 발표했습니다:

매출 $163.58M 예상치 하회 $0, 및 4.32% 전년 대비 성장.
EPS -0.03 예상치 상회 0.08, 및 62.50% 전년 대비 성장.

다음 실적 발표

OPKO Health Inc.의 실적 발표 예정일은 Oct 28, 2026, 장 마감 후입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

3일 전 · Zacks

OPK Raises $125 Million Against Royalties: What Investors Should Know

OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.

3일 전 · Zacks

Is OPK Worth Buying as Valuation Meets Improving Business Trends?

OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.

3일 전 · Zacks

OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?

OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.

4일 전 · Zacks

OPKO Health Secures $125 Million Financing Against Mazdutide Royalties

OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.

2주 전 · Zacks

OPKO Health (OPK) Upgraded to Buy: Here's What You Should Know

OPKO Health (OPK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 페이지 중 1

OPKO Health Inc. (OPK)